Secondary resistance to bromocriptine and cabergoline therapy in hyperprolactinemia: One case of pregnancy with IVF-ET

L. Liang, Lu Wang, Qiaohua He, Cuilian Zhang, Hang-sheng Li
{"title":"Secondary resistance to bromocriptine and cabergoline therapy in hyperprolactinemia: One case of pregnancy with IVF-ET","authors":"L. Liang, Lu Wang, Qiaohua He, Cuilian Zhang, Hang-sheng Li","doi":"10.15761/jpr.1000159","DOIUrl":null,"url":null,"abstract":"Background: For patients with hyperprolactinemia, primary dopamine agonist resistance occurs in 10-15%, secondary resistance following initial biochemical and anti-proliferative response is very rare and has only been described in five previous cases. For women of childbearing age, hyperprolactinemia affects follicular development, potentially causing infertility. Currently, reports on pregnancy outcomes of secondary dopamine resistance in patients with unexplained hyperprolactinemia are scarce. In this paper, we report one case of pregnancy with unexplained bromocriptineand cabergoline-resistant hyperprolactinemia, with follow-up data for four years after birth. Case report: The 32-year-old patient had been diagnosed with primary infertility for four years.She has been treated with dopamine agonist therapy for 3 years. At first, she was initially treated with bromocriptine, marked reduction in prolactin concentration. After one years her prolactin concentration began to rise despite escalating doses of bromocriptine up to six tablets/day and cabergoline up 6mg weekly(two tablets each time, three times per week). Hypothalamic-pituitary lesions and other lesions were ruled out. After ovulation induction, the development and ovulation of dominant follicles were observed only occasionally. The patient failed to become pregnant after intrauterine insemination (IUI) . However, after one cycle of IVF-ET(in vitro fertilization-embryo transfer)the patient became pregnant. She delivered a baby girl at full term, and the baby was normal over the course of the four-year follow-up. Conclusion: While the mechanism of secondary resistance remains unknown and not possible to predict, the woman can become pregnant after IVF-ET, even if the PRL level remains higher than normal. *Correspondence to: Hangsheng Li, Reproductive Medical Center, the Affiliated People's Hospital of Zhengzhou University, Zhengzhou, China, Tel: +8613523585116; E-mail: xiaohongfan0617@126.com","PeriodicalId":166070,"journal":{"name":"Journal of Pregnancy and Reproduction","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pregnancy and Reproduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/jpr.1000159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: For patients with hyperprolactinemia, primary dopamine agonist resistance occurs in 10-15%, secondary resistance following initial biochemical and anti-proliferative response is very rare and has only been described in five previous cases. For women of childbearing age, hyperprolactinemia affects follicular development, potentially causing infertility. Currently, reports on pregnancy outcomes of secondary dopamine resistance in patients with unexplained hyperprolactinemia are scarce. In this paper, we report one case of pregnancy with unexplained bromocriptineand cabergoline-resistant hyperprolactinemia, with follow-up data for four years after birth. Case report: The 32-year-old patient had been diagnosed with primary infertility for four years.She has been treated with dopamine agonist therapy for 3 years. At first, she was initially treated with bromocriptine, marked reduction in prolactin concentration. After one years her prolactin concentration began to rise despite escalating doses of bromocriptine up to six tablets/day and cabergoline up 6mg weekly(two tablets each time, three times per week). Hypothalamic-pituitary lesions and other lesions were ruled out. After ovulation induction, the development and ovulation of dominant follicles were observed only occasionally. The patient failed to become pregnant after intrauterine insemination (IUI) . However, after one cycle of IVF-ET(in vitro fertilization-embryo transfer)the patient became pregnant. She delivered a baby girl at full term, and the baby was normal over the course of the four-year follow-up. Conclusion: While the mechanism of secondary resistance remains unknown and not possible to predict, the woman can become pregnant after IVF-ET, even if the PRL level remains higher than normal. *Correspondence to: Hangsheng Li, Reproductive Medical Center, the Affiliated People's Hospital of Zhengzhou University, Zhengzhou, China, Tel: +8613523585116; E-mail: xiaohongfan0617@126.com
高泌乳素血症患者对溴隐亭和卡麦角林治疗的继发性耐药:1例IVF-ET妊娠
背景:对于高泌乳素血症患者,原发性多巴胺激动剂耐药发生率为10-15%,初始生化和抗增殖反应后的继发性耐药非常罕见,仅在先前的5例病例中被描述。对于育龄妇女,高催乳素血症影响卵泡发育,可能导致不孕。目前,关于不明原因高泌乳素血症患者继发性多巴胺抵抗妊娠结局的报道很少。在本文中,我们报告了一例妊娠不明原因的溴隐亭和卡麦角碱耐药高泌乳素血症,并随访了出生后四年的数据。病例报告:32岁患者被诊断为原发性不孕症四年。她已经接受了3年的多巴胺激动剂治疗。起初,她最初用溴隐亭治疗,催乳素浓度明显降低。一年后,她的催乳素浓度开始上升,尽管溴芥子碱的剂量逐渐增加到每天6片,卡麦角林每周增加到6mg(每次2片,每周3次)。排除下丘脑-垂体病变及其他病变。诱导排卵后,优势卵泡的发育和排卵仅偶见。患者经宫内人工授精(IUI)后未成功怀孕。然而,经过一个周期的IVF-ET(体外受精-胚胎移植)后,患者怀孕了。她在足月生下了一名女婴,在四年的随访过程中,婴儿一切正常。结论:虽然继发性耐药的机制尚不清楚,也无法预测,但即使PRL水平仍高于正常水平,妇女也可以在IVF-ET后怀孕。*通讯:李航生,郑州大学附属人民医院生殖医学中心,中国郑州,电话:+8613523585116;电子邮件:xiaohongfan0617@126.com
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信